Andro Yuson
Reducing variability in care for this patient population is critical to early identification and improving patient outcomes…
On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.
“These findings are extremely important and complementary to the recently presented EARLY TAVR Trial, published in the NEJM. The absence of symptoms was traditionally considered a sign of relative safety. However, this study shows how frequent acute valve syndrome is in patients undergoing AVR, and how patients would benefit greatly
© 2024 egnite, Inc. All Rights Reserved. egnite, egnite Inc., CardioCare, the heart logo, and the spark logo are trademarks of egnite, Inc. All other trademarks are property of their respective owners.
Privacy Policy Intellectual Property Terms of Use Implementation Kit Careers